University of South Florida

Digital Commons @ University of South Florida
USF St. Petersburg campus Faculty
Publications

USF Faculty Publications

2020

Antimicrobial and Antibiofilm Activities of Probiotic Lactobacilli
on Antibiotic-Resistant Proteus mirabilis
Mona Shaaban
Ola A. Abd El-Rahman
Bashair Al-Qaidi
Hossam M. Ashour
University of South Florida St. Petersburg, ashour@mail.usf.edu

Follow this and additional works at: https://digitalcommons.usf.edu/fac_publications

Recommended Citation
Shaaban, M., Abd El-Rahman, O. A., Al-Qaidi, B., & Ashour, H. M. (2020). Antimicrobial and Antibiofilm
Activities of Probiotic Lactobacilli on Antibiotic-Resistant Proteus mirabilis. Microorganisms, 8(6), 960.
doi:10.3390/microorganisms8060960

This Article is brought to you for free and open access by the USF Faculty Publications at Digital Commons @
University of South Florida. It has been accepted for inclusion in USF St. Petersburg campus Faculty Publications
by an authorized administrator of Digital Commons @ University of South Florida. For more information, please
contact scholarcommons@usf.edu.

microorganisms
Article

Antimicrobial and Antibiofilm Activities of Probiotic
Lactobacilli on Antibiotic-Resistant Proteus mirabilis
Mona Shaaban 1,† , Ola A. Abd El-Rahman 2,† , Bashair Al-Qaidi 3 and Hossam M. Ashour 4,5, *
1
2
3
4
5

*
†

Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University,
Mansoura 35516, Egypt
Department of Microbiology and Immunology, Faculty of Pharmacy (Girls), Al-Azhar University,
Cairo 11651, Egypt
Madinah Maternity and Children Hospital, Madinah 42319, Saudi Arabia
Department of Biological Sciences, College of Arts and Sciences, University of South Florida St. Petersburg,
St. Petersburg, FL 33701, USA
Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
Correspondence: hossamking@mailcity.com
Both authors contributed equally to this work.



Received: 6 June 2020; Accepted: 23 June 2020; Published: 26 June 2020

Abstract: The emergence of biofilm-forming, multi-drug-resistant (MDR) Proteus mirabilis infections is
a serious threat that necessitates non-antibiotic therapies. Antibiotic susceptibility and biofilm-forming
activity of P. mirabilis isolates from urine samples were assessed by disc diffusion and crystal violet
assays, respectively. Antimicrobial activities of probiotic Lactobacilli were evaluated by agar diffusion.
Antibiofilm and anti-adherence activities were evaluated by crystal violet assays. While most P. mirabilis
isolates were antibiotic-resistant to varying degrees, isolate P14 was MDR (resistant to ceftazidime,
cefotaxime, amoxicillin-clavulanic acid, imipenem, ciprofloxacin, and amikacin) and formed strong
biofilms. Cultures and cell-free supernatants of Lactobacillus casei and Lactobacillus reuteri exhibited
antimicrobial and antibiofilm activities. The 1/16 concentration of untreated supernatants of L. casei
and L. reuteri significantly reduced mature biofilm formation and adherence of P14 by 60% and 72%,
respectively (for L. casei), and by 73% each (for L. reuteri). The 1/8 concentration of pH-adjusted
supernatants of L. casei and L. reuteri significantly reduced mature biofilm formation and adherence
of P14 by 39% and 75%, respectively (for L. casei), and by 73% each (for L. reuteri). Scanning electron
microscopy (SEM) confirmed eradication of P14’s biofilm by L. casei. L. casei and L. reuteri could be
utilized to combat Proteus-associated urinary tract infections.
Keywords: Proteus mirabilis; antibiofilm; anti-adherence; Lactobacillus

1. Introduction
Proteus mirabilis is one of the most common pathogens associated with urinary tract infections
(UTI) [1,2]. In addition, it can cause surgical wound infections, biliary tract infections, wound infections,
and nosocomial infections [3]. It is part of the normal gut flora and can cause opportunistic infections
in immunocompromised and elderly patients [3]. The emergence of antibiotic resistance in clinical
isolates of P. mirabilis is a major healthcare issue [4,5]. P. mirabilis poses a major challenge in infection
management as it produces AmpC β-lactamases and extended spectrum β-lactamases [6]. Furthermore,
it can develop complex biofilms with accumulated layers of polysaccharides in which sessile cells are
embedded, which adds to the severity of the infection [7]. The severity, chronicity, and dissemination
of Proteus infections have been mainly attributed to its ability to form biofilms [7].
Probiotics are living microorganisms that belong to Lactobacillus and Bifidobacterium genera [8,9].
The intestinal probiotic Lactobacillus strains have been recognized for their antimicrobial activities
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against enteric bacterial pathogens [10]. Different groups showed that Lactobacillus casei produces
bacteriocins and anti-adherence biosurfactant proteins against Staphylococcus aureus, Bacillus subtilis,
and Micrococcus roseus [11,12]. Human gastrointestinal Lactobacillus reuteri produces a broad-spectrum
antimicrobial called reuterin, which possesses activity against Gram-positive and Gram-negative
enteric pathogens [13]. Probiotic Lactobacilli can also suppress virulence and dissemination of
infectious pathogens [14]. This is typically accomplished through the production of organic acids and
antimicrobials, such as bacteriocins, lipopeptides, and surface proteins [11,15,16].
We have previously shown that probiotic lactobacilli inhibited growth, biofilm formation, and gene
expression of Streptococcus mutans [17]. The anti-infective and anti-colonization properties of probiotic
lacobacilli are of paramount importance in combating various bacterial infections [18,19]. Due to their
antimicrobial properties, probiotics may be considered for treatment and prevention of infectious
diseases caused by oral, enteric, and urogenital pathogens [20,21]. Lactobacilli have been specifically
shown to prevent recurrent urinary tract infections [22]. This indicates their promise as anti-Proteus
agents. Given the antibiotic resistance problem, it is important to develop Lactobacillus-based approaches
to combat Proteus mirabilis-induced urinary tract infections and catheter-associated infections.
In order to be able to better manage P. mirabilis infections, we investigated the potential inhibitory
activities of L. casei and L. reuteri on bacterial growth, mature biofilm formation, and adhesion properties
of multi-drug-resistant (MDR) Proetus mirabilis clinical isolates.
We tested pH-adjusted supernatants of Lactobacillus, which is a commonly used approach in
Lactobacillus probiotic studies to reduce the acidity of the Lactobacillus supernatants and thus assess if
the antimicrobial activity of Lactobacillus products is pH-dependent [23–27]. This is significant given
that studies showed that the acidic pH (due to lactic acid secretion) contributed only a small part of the
activity [28], or did not contribute any additional activity (activity was pH-independent) [29]. In our
study, the pH adjustment was important to reveal how much of the anti-Proteus activity of probiotic
Lactobacillus supernatants was related to non-acidic products and whether the antimicrobial activity of
the supernatant was pH-dependent.
2. Materials and Methods
2.1. Microorganism and Growth Conditions
P. mirabilis isolates were obtained from urine samples collected from several hospitals in Madinah,
KSA (Ohud Hospital, King Fahad Hospital, Al-Ansar Hospital, and Madina Maternity and Children
Hospital). P. mirabilis isolates were identified using biochemical assays and confirmed as P. mirabilis
using the VITEK compact system. Assays included Gram stain, growth characteristics on MacConkey
agar, CLED agar, and triple sugar iron media [30].
Two probiotic strains (L. casei DSM 20011 and L. reuteri DSM 20016) were purchased from MERCEN,
Egypt. Lactobacillus isolates were grown on deMan, Rogosa and Sharpe medium (MRS) and were
anaerobically (AnaeroGen 2.5 L sachets in 2.5 L AnaeroJar AG25, Oxoid Ltd., Hampshire, UK) incubated
at 37 ◦ C [31].
Ethical approvals were obtained from the Institutional Review Boards of the hospitals, ethics
committees of the college of pharmacy, Taibah University, KSA and Faculty of Pharmacy, Mansoura
University, Egypt. Ethical approval code is TUCODRE/20151025/ALQAIDI (in October 2015).
2.2. Antimicrobial Susceptibility of P. mirabilis Isolates
P. mirabilis isolates were tested for their resistance to different antimicrobials using the disk
diffusion method [32]. The antimicrobials used were amoxicillin-clavulanic acid (AMC; 30 mg),
imipenem (IMP; 10 mg), cefoxitin (FOX; 30 mg), ceftazidime (CAZ; 30 mg), ciprofloxacin (CIP; 5 mg),
cefotaxime; (CTX; 30 mg), and amikacin (AK; 30 mg) (Bioanalyse, Ankara, Turkey).
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2.3. Detection of Biofilm Formation by P. mirabilis Isolates
The mature biofilm of P. mirabilis isolates was formed in flat-bottomed 96-well microtiter plates.
The overnight culture of each isolate was adjusted to 0.5 McFarland (1.5 × 108 CFU/mL) using Muller
Hinton broth. Then, 200 µL of the diluted cultures was distributed in each well and incubated at 37 ◦ C
for 48 h. The planktonic cells were removed and the attached cells were gently washed twice with
sterile physiological saline. Then, 200 µL of methanol (99%) was added to each well and retained
for 15 min to fix the sessile cells. The methanol was discarded, and the plate was left until complete
dryness. To stain the adherent cells, 200 µL of 2% w/v crystal violet solution was added to each well and
was left for 20 min. The wells were washed gently and left to dry. Glacial acetic acid (200 µL; 33% w/v)
was added to release the bound dye and the absorbance was measured at OD540 nm using ELISA
microplate reader (MR-960, Perlong Medical Equipment Co. Ltd., Nanjing, China). Depending on the
optical density (OD) generated by the bacterial biofilms, the tested P. mirabilis isolates were classified
into non-biofilm producers, weak biofilm producers, moderate biofilm producers, and strong biofilm
producers [33]. The cut-off OD of the negative control (ODc) was determined by adding the mean
of the negative control to three standard deviations of it. The lack of biofilm formation is indicated
by ODs ≤ ODc for the tested isolates. Weak biofilm production is indicated by ODc < OD ≤ (2 ODc).
Moderate biofilm formation is indicated by (2 ODc) < O.D. ≤ (4 ODc). Strong biofilm formation is
indicated by (4 ODc) < O.D. Tests were conducted in triplicates.
2.4. Preparation of Cell-Free Supernatant from Lactobacillus Strains
In order to prepare the Lactobacillus culture, the MRS medium was inoculated with Lactobacillus
strains with inoculum size 1% v/v and was incubated anaerobically at 37 ◦ C for 48 h. The grown culture
was centrifuged at 6000 rpm for 15 min to separate all cells and the supernatant was filtered through a
0.22 µm membrane filter. The cell-free supernatant was labeled as untreated supernatant (U) and stored
at −20 ◦ C. The Lactobacillus supernatant was highly acidic due to lactic acid production. To adjust the
pH of the supernatant to pH 6.5–7.0, 1N NaOH was used and this fraction of the supernatant was
labeled as treated supernatant (T) and stored at −20 ◦ C [34].
2.5. Antimicrobial Activity of Lactobacillus Supernatants
The antimicrobial activity of Lactobacillus supernatants (treated or untreated) was assessed against
the P. mirabilis isolates P2, P4, P14, P15, P23, P24 and P25 using microtiter plate assays. The antibacterial
activity was assayed by the agar diffusion method [35]. The P. mirabilis isolates were incubated in Muller
Hinton broth at 37 ◦ C for 24 h. The culture inoculum was adjusted to 0.5 McFarland (1.5 × 108 CFU/mL)
and was used to inoculate melted Muller Hinton agar at 50 ◦ C. After medium solidification, wells were
cut in agar using a cork borer. Wells were filled with 100 µL of the whole cell culture of Lactobacillus or
cell-free supernatants (treated or untreated), and the plates were incubated aerobically at 37 ◦ C for 24 h.
Inhibition zones were measured to indicate the antimicrobial activity of the corresponding Lactobacillus.
Stock solutions of treated or untreated Lactobacillus supernatants were maintained, and different
concentrations 1/2, 1/4, 1/18, 1/16, and 1/32 were prepared.
2.6. Effect of Lactobacillus Supernatant on Mature Biofilms
The mature biofilms of P. mirabilis isolates P2, P4, P14, P15, P23, P24, and P25 were formed in
flat-bottomed 96-well microtiter plates. The overnight culture of each isolate was adjusted to 0.5
McFarland using Muller Hinton broth. Then, 100 µL of the diluted Proteus cultures was added to each
well and incubated at 37 ◦ C for 48 h. The planktonic cells were removed and the attached cells were
gently washed twice with sterile physiological saline. Untreated or treated supernatants of Lactobacillus
were then added to the wells and the plates were incubated at 37 ◦ C for 24 h. The biofilm of each
Proteus isolate without Lactobacillus supernatants was used as a positive control. The influence of
different concentrations of Lactobacillus supernatants (treated or untreated) on the mature biofilm was
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detected using crystal violet microtiter plate assays. The treated and the mature Proteus biofilms were
washed, fixed using methanol, and stained with crystal violet as described before [36].
The effects of different concentrations (1/2, 1/4, 1/18, 1/16, and 1/32) of treated and untreated
supernatants of L. casei and L. reuteri on the mature biofilms of the P. mirabilis isolate P14 were
also evaluated.
2.7. Anti-Adherence Effect of Lactobacillus Supernatants
In order to study the effect of Lactobacillus on biofilm formation, 100 µL of treated or untreated
supernatants of Lactobacillus was mixed at low concentrations (1/8, 1/16 and 1/32) with 100 µL
of the P. mirabilis isolate P14 (with inoculum size 1.5 × 108 CFU/mL). The microtiter plate was
incubated for 48 h at 37 ◦ C and the biofilm formation was detected using the crystal violet microtiter
plate method [17]. Wells containing the Proteus isolate P14 in contact with different concentrations
of Lactobacillus supernatant (At) were compared to wells containing Proteus culture without the
Lactobacillus supernatant (control, Ac). The percent reduction in biofilm formation was calculated as
follows = ((Ac − At)/Ac) ×100.
2.8. Scanning Electron Microscopy (SEM)
The overnight culture of P14 was diluted to 0.5 McFarland using tryptic soy broth (TSB). Similarly,
cultures of the tested Lactobacillus strains were diluted in MRS and co-cultured with equal volumes of
P14 (1:1) in sterile six well plates (Greiner Bio-One, Kremsmünster, Austria) at 37 ◦ C for 24 h. The control
wells containing P14 only with MRS and TSB media were also prepared. A clean sterile cover slide
was added to each well. The slides were removed and washed gently with phosphate buffered saline
(PBS) to remove the planktonic cells. The biofilm was fixed and prepared for examination by SEM
(JSM-7600F, JEOL USA, INC., Peabody, MA, USA) as previously described [37].
2.9. Statistical Analysis
Statistical analysis was performed using one-way ANOVA in order to compare the effect of
Lactobacillus, cell-free, and treated supernatants on the mature biofilm and on the adhesion of P. mirabilis
isolates. A p value of <0.05 indicated statistical significance.
3. Results
3.1. Antimicrobial Susceptibility and Biofilm Formation of P. mirabilis isolates
Activity of the tested antimicrobial agents against P. mirabilis isolates was evaluated according
to CLSI standards [32]. As shown in Table 1, 86% of the tested P. mirabilis isolates were resistant
to amoxicillin-clavulanic, 57% were resistant to cefotaxime, 57% were resistant to ceftazidime, 71%
were resistant to ciprofloxacin, 57% were resistant to amikacin, 43% were resistant to imipenem, and
0% were resistant to cefoxitin. Furthermore, isolate P14 was resistant to cefotaxime, ceftazidime,
amoxicillin-clavulanic acid, ciprofloxacin, and amikacin and intermediately resistant to imipenem
(Table 1). In contrast, isolate P2 was sensitive to all the assessed antimicrobials (Table 1).
P. mirabilis isolates P2, P4, P14, P24 and P25 showed strong biofilm formation. Isolates P15 and
P23 showed moderate biofilm formation. Isolate P14 showed the strongest biofilm formation and was
resistant to the tested antimicrobials. Isolate P2 showed a strong biofilm formation, but was sensitive
to all assessed antimicrobials.
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Table 1. Antimicrobial susceptibility patterns of P. mirabilis isolates.
Isolate
No.

FOX
30 mg

CAZ
30 mg

CTX
30 mg

AMC
30 mg

IMP
10 mg

CIP
5 mg

AK
30 mg

Biofilm
Formation

P2
P4
P14
P15
P23
P24
P25

S
S
S
S
S
S
S

S
S
R
S
R
R
R

S
S
R
S
R
R
R

S
R
R
I
R
R
R

S
I
I
I
S
S
S

S
I
R
S
R
R
R

S
S
R
S
R
R
R

Strong
Strong
Strong
Moderate
Moderate
Strong
Strong

FOX: Cefoxitin; CAZ: Ceftazidime; CTX: Cefotaxime; AMC: Amoxicillin-Clavulanic acid; IMP: Imipenem; CIP:
Ciprofloxacin and AK: Amikacin. S: Sensitive, R: Resistant, and I: Intermediate.

3.2. Antimicrobial Activities of L. casei and L. reuteri against P. mirabilis Isolates
The untreated supernatants of L. casei and L. reuteri had inhibitory effects on the tested P. mirabilis
isolates (Table 2). The treated (pH-adjusted) supernatants of L. reuteri were effective against almost
all tested P. mirabilis isolates with inhibition zone diameters ranging from 12 to 16 mm. The treated
(pH-adjusted) supernatants of L. casei was effective against four isolates (P2, P14, P15 and P24) with
inhibition zone diameters ranging from 13 to 16 mm. Notably, the treated supernatants of L. casei and
L. reuteri were effective against the multidrug resistant (MDR) Proteus isolate P14 with inhibition zone
diameters ranging from 14 to 15 mm (Table 2).
Table 2. Antimicrobial activities of L. casei and L. reuteri against P. mirabilis isolates.
Inhibition Zone Diameter (mm)
L. casei
DSM 20011

Isolate No.

P2
P4
P14
P15
P23
P24
P25

L. reuteri
DSM 20016

C

T

U

C

T

U

20
20
18
20
19
20
20

13
14
16
14
-

20
21
18
20
20
20
20

20
21
20
20
20
20
20

15
16
14
15
15
12
-

20
20
20
18
20
19
18

C: The Lactobacillus Culture; T: The treated (pH-adjusted) cell-free supernatants of Lactobacillus; U: The untreated
cell-free supernatants of Lactobacillus; -: No effect.

3.3. Effect of Lactobacillus Supernatants on Mature Biofilm Formation of P. mirabilis Isolates
The effect of treated and untreated supernatants of L. casei and L. reuteri on mature biofilm
formation of P. mirabilis isolates P2, P4, P14, P15, P23, P24, and P25 was studied (Figure 1).
The untreated supernatants of L. casei significantly reduced biofilm formation of isolates P2,
P4, P14, P15, P23, P24, and P25 by 56%, 70%, 48%, 45%, 49%, 50%, and 67%, respectively (p < 0.05)
(Figure 1A). Furthermore, the treated supernatants of L. casei significantly reduced biofilm formation
of isolates P2, P4, P14, P15, P23, P24, and P25 by 61%, 29%, 40%, 60%, 36%, 32%, and 32%, respectively
(p < 0.05) (Figure 1B).
Similarly, the untreated supernatants of L. reuteri significantly reduced biofilm formation of
isolates P2, P4, P14, P15, P23, P24, and P25 by 46%, 65%, 52%, 48%, 58%, 62%, and 65%, respectively
(p < 0.05) (Figure 1A). Moreover, the treated supernatants of L. reuteri significantly reduced biofilm
formation of isolates P2, P4, P14, P15, P23, P24, and P25 by 60%, 45%, 66%, 67%, 52%, 52%, and 69%,
respectively (p < 0.05) (Figure 1B).
In brief, the treated and the untreated supernatants of L. casei, and L. reuteri caused significant
reductions of mature biofilm formation in the tested P. mirabilis isolates (p < 0.05) (Figure 1).
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3.4. Anti-Adherence Effect of Lactobacillus Supernatants
The anti-adherence effect of diluted Lactobacillus supernatants (treated and untreated) on the P14
isolate was assessed. As in Figure 3, the untreated supernatants of L. casei and L. reuteri significantly
reduced the adhesion of the P14 isolate (1/16 concentration) by 72% and 73%, respectively (p < 0.01)
(Figure 3A, C). The anti-adherence effect of the untreated supernatants on the P14 isolate decreased
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The 1/16 and 1/32 concentrations of the untreated supernatants of L. reuteri caused a significant
reduction in biofilm formation of the P14 isolate by 73% and 32%, respectively (p < 0.05) (Figure 2C).
The 1/8 concentration of the treated supernatants of L. reuteri significantly reduced biofilm formation
of the P14 isolate by 73% (p < 0.05) (Figure 2D).
3.4. Anti-Adherence Effect of Lactobacillus Supernatants
The anti-adherence effect of diluted Lactobacillus supernatants (treated and untreated) on the P14
isolate was assessed. As in Figure 3, the untreated supernatants of L. casei and L. reuteri significantly
reduced the adhesion of the P14 isolate (1/16 concentration) by 72% and 73%, respectively (p < 0.01)
(Figure 3A,C). The anti-adherence effect of the untreated supernatants on the P14 isolate decreased by
further diluting the supernatant.
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P14 (Figure 4B). Co-culture of L. reuteri with P. mirabilis P14 showed scattered cells and a loose biofilm
architecture but no dense aggregates (Figure 4C).
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Figure 4. Scanning Electron micrographs (SEM) (magnification: × 15,000). (A) Biofilm formation of the
8
P14 isolate in the absence of Lactobacillus spp. (control).
(B) Biofilm formation of the P14 isolate in the
presence of L. casei. (C) Biofilm formation of the P14 isolate in the presence of L. reuteri.

4. Discussion
Bacterial resistance is one of the major public health problems. It includes the emergence of MDR
pathogens, such as resistant isolates of Proteus mirabilis, which have been associated with urinary
tract infections and nosocomial infections worldwide [4,38]. P. mirabilis isolates have been reported
to be resistant to penicillins [39]. They also show a high incidence of resistance to cephalosporins,
carbapenems, and quinolones [4,40]. In the current study, a high percentage of the isolates was resistant
or intermediately resistant to amoxicillin-clavulanic acid and cefotaxime. There was also significant
resistance to ceftazidime, ciprofloxacin, and amikacin (Table 1). It is noteworthy that the isolate P14
was resistant to three different groups of antibiotics with various mechanisms of action (Table 1).
Cefotaxime-resistant P. mirabilis has been previously described [41]. Kwiecińska-Piróg et al. reported
that P. mirabilis showed resistance against ceftazidime and ciprofloxacin [42]. Amikacin resistance has
been shown to be associated with extended spectrum beta-lactamase (ESBL(-producing isolates of
P. mirabilis, which were resistant to amikacin (85.1%) [43].
Urinary tract infection with P. mirabilis is associated with biofilm formation and accumulation of
the polysaccharide matrix [44]. This is followed by urease production, increase in the pH, attraction
of calcium and magnesium ions, and development of crystals [44]. The deposition of crystals
within the biofilm can cause catheter blockage and urinary retention. This is because P. mirabilis
possesses various virulence factors (lipopolysaccharide, quorum sensing autoinducers, pili, adhesin,
and other proteins) that enhance adhesion and crystalline biofilm formation on the abiotic surfaces
of urinary catheters [45]. It has been reported that 48% of the isolated proteus species were biofilm
producers [42]. The Proteus-biofilm assembly is dangerous, as it interferes with microbial penetration,
increases antimicrobial resistance, and renders therapeutic treatments ineffective, which encourages
the development and chronicity of infections [46].
Moreover, pathogenicity of P. mirabilis is enhanced by the complex architecture of its biofilm,
which is characterized by a high ability for adapting to different environmental conditions, biocides,
and antimicrobials [47,48]. Isolates in this study were able to form strong or moderate biofilms. This was
true even for the antibiotic-sensitive isolate P2, which was observed to have a strong biofilm-forming
ability (Table 1). Typically, the biofilm-producing isolates are more resistant to antibiotics than the
non-biofilm producing isolates [49]. The reason is that the development of complex biofilm structures

Microorganisms 2020, 8, 960

9 of 13

can convey protection to the internal cells from antimicrobials [50]. It can also support the persistence
of P. mirabilis in the host cells [50].
Given the above, alternative treatments are required for the management of P. mirabilis infections
and the disruption of its biofilm architecture. Probiotics as Lactobacilli, have been used for the treatment
of burn infections and have been shown to interfere with activity of Pseudomonas aeruginosa [51,52].
Lactobacilli have also been used for the management of recurrent urinary tract infections caused
by E. coli [53]. The antimicrobial activity of L. casei and L. reuteri against various enteropathogenic
infections have been previously reported [10]. Their antimicrobial activities against uropathogens have
also been reported [20]. L. reuteri has been shown to be effective against Escherichia coli and Listeria
monocytogenes [54]. Thus, it was important to examine the antimicrobial and antibiofilm activities of
Lactobacillus on P. mirabilis clinical isolates. We examined the cultures and the cell-free supernatants of
L. casei, and L. reuteri against P. mirabilis isolates.
In our study, the treated supernatants of L. casei and L. reuteri retained antimicrobial activities
against the sensitive P2 isolate and the other resistant Proteus mirabilis isolates (Table 2). Notably, treated
supernatants of L. casei and L. reuteri retained significant antibiofilm and anti-adherence activities
against P14 at 1/8 concentration (Figures 2 and 3). In addition, L. casei and L. reuteri had significant
inhibitory effects on the typical biofilm formed by the MDR isolate P14, as detected by SEM (Figure 4).
In another study, the untreated supernatants of fecal Lactobacilli caused an 85 to 95% reduction in
biofilm formation of Vibrio cholerae isolates [27]. Similarly, the pH-adjusted supernatants of fecal
Lactobacilli significantly reduced biofilm formation of Vibrio cholerae by 50–75% [27]. Additionally,
Koohestani and colleagues showed that the untreated supernatants of L. casei significantly reduced
biofilm formation of S. aureus [55]. Probiotic lactobacilli have been shown to negatively impact growth
and biofilm formation of Streptococcus mutans [34], pathogens in the oral cavity [56], and Salmonella
enterica serovar Typhimurium [28]. Moreover, probiotic lactobacilli inhibited cancer cells of the human
colonic carcinoma cell line HT-29 [23]. Lastly, Lactobacillus reuteri DPC16 supernatants have been shown
to exhibit activity against Escherichia coli, S. aureus, Salmonella derby, and Listeria monocytogenes. This is
consistent with results in our study in which the untreated supernatants of L. casei reduced biofilm
formation of P. mirabilis isolates by 45–67%.
It is important to mention that the use of probiotic Lactobacillus cell cultures and supernatants was
proposed as an alternative to traditional antibiotic therapy against P. mirabilis. In other words, it was
proposed as a way to avoid the adverse effects of antibiotic therapy and to circumvent the impact
of antibiotic resistance developed by the microbe. Indeed, we saw a significant inhibitory effect of
Lactobacillus cell cultures and supernatants on P. mirabilis biofilm formation and adherence. Future
studies could examine the effect of Lactobacillus supernatants on the susceptibility of P. mirabilis to the
tested antimicrobials. In this case, the focus would be on the possible synergistic effects of combining
probiotic Lactobacillus supernatants with anti-Proteus agents.
The antimicrobial, antibiofilm, and anti-adherence activities of probiotic L. casei and L. reuteri
used in this study could be attributed to their secreted biosurfactants [15], S-layer proteins [57,58],
surface-acting proteins (such as enolase) [59], and peptidoglycan-binding proteins [60].
5. Conclusions
The pathogenicity and virulence of Proteus infections includes a biofilm-forming ability that enables
serious urinary tract infection. Isolates in this study showed multidrug resistance (MDR) against
more than one antimicrobial agent, highlighting the importance of the development of alternative and
adjuvant treatments for the efficient management of P. mirabilis infections. Using cell cultures, cell-free
supernatants, and pH-adjusted supernatants, we have shown that L. casei DSM 20011 and L. reuteri
DSM 20016 exhibit antimicrobial, anti-adherence, and antibiofilm activities against MDR P. mirabilis.
Thus, L. casei and L. reuteri could be utilized to combat Proteus-associated urinary tract infections.
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